Atorvastatin Exerts More Selective Inhibitory Effects on hMCT2 than on hMCT1 and hMCT4
Anticancer Research · 2023
DOI: 10.21873/anticanres.16472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Atsushi Yamaguchi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hokkaido University Hospital, Sapporo, Japan. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Hokkaido University Hospital, Sapporo, Japan.
- Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
- Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan masaki@pharm.hokudai.ac.jp.
Zitieren
APA
Yamaguchi, A., Mukai, Y., Sakuma, T., Furugen, A., Narumi, K., & Kobayashi, M. (2023). Atorvastatin Exerts More Selective Inhibitory Effects on hMCT2 than on hMCT1 and hMCT4. Anticancer Research. https://doi.org/10.21873/anticanres.16472
Vancouver
Yamaguchi A, Mukai Y, Sakuma T, Furugen A, Narumi K, Kobayashi M. Atorvastatin Exerts More Selective Inhibitory Effects on hMCT2 than on hMCT1 and hMCT4. Anticancer Research. 2023. doi:10.21873/anticanres.16472
BibTeX
@article{Yamaguchi2023,
author = {Yamaguchi, Atsushi and Mukai, Yuto and Sakuma, Tomoya and Furugen, Ayako and Narumi, Katsuya and Kobayashi, Masaki},
title = {Atorvastatin Exerts More Selective Inhibitory Effects on hMCT2 than on hMCT1 and hMCT4},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16472}
}
EUVIMED